

Trends in the pharmacological management of atrial fibrillation in UK general practice 2008-2018

Phillips, Katherine; Subramanian, Anuradha; Thomas, G Neil; Khan, Nazish; Chandan, Joht; Brady, Paul; Marshall, Tom; Nirantharakumar, Krishnarajah; Fabritz, Larissa; Adderley, Nicola

DOI:

[10.1136/heartjnl-2021-319338](https://doi.org/10.1136/heartjnl-2021-319338)

License:

Creative Commons: Attribution-NonCommercial (CC BY-NC)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Phillips, K, Subramanian, A, Thomas, GN, Khan, N, Chandan, J, Brady, P, Marshall, T, Nirantharakumar, K, Fabritz, L & Adderley, N 2022, 'Trends in the pharmacological management of atrial fibrillation in UK general practice 2008-2018', *Heart*, vol. 108, no. 7, 319338, pp. 517-522. <https://doi.org/10.1136/heartjnl-2021-319338>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This article has been accepted for publication in *Heart*, 2021 following peer review, and the Version of Record can be accessed online at: <http://dx.doi.org/10.1136/heartjnl-2021-319338>

© Author(s) (or their employer(s)). Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) <http://creativecommons.org/licenses/by-nc/4.0/>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.




When citing, please reference the published version.


Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.


If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Supplementary Figures






Supplementary Figure 3: Percentage of patients at high risk of stroke (CHA2DS2-VASc ≥ 2) prescribed rate control drugs 2008-2018



Supplementary Figure 4a: Percentage of patients with heart failure prescribed rate control drugs 2008-2018



Supplementary Figure 4b: Percentage of patients without heart failure prescribed rate control drugs 2008-2018

